Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CULTIVATE trial of oral etrasimod in moderately to severely active Crohn's disease
jRCT2031210551Completed
- Sponsor
- Pfizer
- Start
- Jul 2022
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of etrasimod in Crohn's disease (3 arms), sponsored by Pfizer. Primary endpoints: Number and severity of adverse events, Proportion of participants with endoscopic response and 1 more. Started Jul 2022; status: completed.
02
Drugs
etrasimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2031210551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210551.